Quantitation of 3-deoxyglucosone levels in human plasma

Archives of Biochemistry and Biophysics
S LalT R Brown

Abstract

3-Deoxyglucosone (3DG), a reactive dicarbonyl, is an important intermediate in the formation of advanced glycation end products (AGEs). The AGEs are particularly important in diabetes since they have been correlated with the development of diabetic complications. Consequently, measurements of 3DG are likely to provide valuable insights into the role of this metabolite in the etiology of diabetic complications. While several methods of 3DG quantitation in human plasma have been previously published, a significant discrepancy (over 30-fold) exists in the reported values. Knecht et al. (Arch. Biochem. Biophys. 294, 130-137, 1992) have reported the levels of plasma 3DG in normoglycemics to be 61 nM, using a GC/MS procedure. In contrast to this, Niwa et al. (Biochem. Biophys. Res. Commun. 196, 837-843, 1993) reported 3DG levels to be 1800 nM in normoglycemics, using a totally independent GC/MS method. To resolve this disagreement and fill the need for a robust assay for this dicarbonyl, suitable for absolute quantitation, a GC/MS procedure was devised for its measurement. Plasma samples were deproteinized either by ultrafiltration or by addition of ethanol as described by Niwa et al. (Biochem. Biophys. Res. Commun. 196, 837-843, 199...Continue Reading

References

Jan 1, 1992·Advances in Pharmacology·R Bucala, A Cerami
Sep 19, 1991·The New England Journal of Medicine·Z MakitaH Vlassara
Jan 26, 1990·Science·B S SzwergoldT R Brown
Jan 1, 1968·Acta Chemica Scandinavica·E Jellum
Apr 1, 1995·Archives of Biochemistry and Biophysics·S LalT R Brown
May 25, 1995·Biochemical and Biophysical Research Communications·E FujiiK Hotta
Jan 10, 1995·Archives of Biochemistry and Biophysics·D V ZyzakJ W Baynes
Feb 22, 1995·Biochimica Et Biophysica Acta·M Portero-OtinV M Monnier
Oct 29, 1993·Biochemical and Biophysical Research Communications·T NiwaK Niimura
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Feb 15, 1993·European Journal of Biochemistry·S A Phillips, P J Thornalley
Jan 1, 1992·Bioscience, Biotechnology, and Biochemistry·Z Q LiangH Kato

❮ Previous
Next ❯

Citations

Oct 6, 2009·Matrix Biology : Journal of the International Society for Matrix Biology·Sihem Sassi-GahaCarol M Artlett
Aug 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Yukiko HasuikeYoshihiro Takamitsu
Feb 18, 2011·Mass Spectrometry Reviews·Toshimitsu Niwa
Jul 28, 2004·Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology·K Kagawa, H Kagawa
Nov 16, 2004·Biochemical and Biophysical Research Communications·Yoshiaki UchidaSatoru Ito
Oct 22, 2014·Journal of the Science of Food and Agriculture·Ana I Ruiz-MatuteIsabel Martínez-Castro
May 27, 2003·Diabetes Care·Hitomi KusunokiMasato Kasuga
Jul 29, 2003·Diabetes·Roya Babaei-JadidiPaul J Thornalley
Apr 8, 2016·Molecular Medicine Reports·Guoqiang LiangGuorong Jiang
Sep 11, 2020·BioMed Research International·Jin CaiFei Huang
Jul 23, 1999·Archives of Biochemistry and Biophysics·P Chellan, R H Nagaraj
Sep 24, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·T Niwa
Sep 24, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·S TsukushiT Niwa
Mar 4, 2014·Journal of Agricultural and Food Chemistry·Julia DegenThomas Henle
Dec 28, 2010·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·A I Ruiz-MatuteI Martínez-Castro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.